{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:31:36Z","timestamp":1793320296134,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"crossref","award":["136836"],"award-info":[{"award-number":["136836"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the developed world. EOC metastasis is unique since malignant cells detach directly from the primary tumor site into the abdominal fluid and form multicellular aggregates, called spheroids, that possess enhanced survival mechanisms while in suspension. As such, altered cell adhesion properties are paramount to EOC metastasis with cell detachment from the primary tumor, dissemination as spheroids, and reattachment to peritoneal surfaces for secondary tumor formation. The ability for EOC cells to establish and maintain cell\u2013cell contacts in spheroids is critical for cell survival in suspension. Integrins are a family of cell adhesion receptors that play a crucial role in cell\u2013cell and cell-extracellular matrix interactions. These glycoprotein receptors regulate diverse functions in tumor cells and are implicated in multiple steps of cancer progression. Altered integrin expression is detected in numerous carcinomas, where they play a role in cell migration, invasion, and anchorage-independent survival. Like that observed for other carcinomas, epithelial-mesenchymal transition (EMT) occurs during metastasis and integrins can function in this process as well. Herein, we provide a review of the evidence for integrin-mediated cell adhesion mechanisms impacting steps of EOC metastasis. Taken together, targeting integrin function may represent a potential therapeutic strategy to inhibit progression of advanced EOC.<\/jats:p>","DOI":"10.1007\/s10585-021-10136-5","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T06:07:10Z","timestamp":1637820430000},"page":"291-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: a review"],"prefix":"10.1007","volume":"39","author":[{"given":"Dolly","family":"Dhaliwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-8066","authenticated-orcid":false,"given":"Trevor G.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"10136_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM (2019) Epithelial ovarian cancer. Lancet 393:1240\u20131253","journal-title":"Lancet"},{"key":"10136_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"key":"10136_CR3","first-page":"609","volume":"80","author":"MA Roett","year":"2009","unstructured":"Roett MA, Evans P (2009) Ovarian cancer: An overview. Am Fam Physician 80:609\u2013616","journal-title":"Am Fam Physician"},{"key":"10136_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00404-016-4035-8","volume":"293","author":"I Meinhold-Heerlein","year":"2016","unstructured":"Meinhold-Heerlein I, Fotopoulou C, Harter P et al (2016) The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet 293:695\u2013700. https:\/\/doi.org\/10.1007\/s00404-016-4035-8","journal-title":"Arch Gynecol Obstet"},{"key":"10136_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10555-012-9351-2","volume":"31","author":"KL Sodek","year":"2012","unstructured":"Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ (2012) Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev 31:397\u2013414. https:\/\/doi.org\/10.1007\/s10555-012-9351-2","journal-title":"Cancer Metastasis Rev"},{"key":"10136_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/932371","volume":"2010","author":"AM Karst","year":"2010","unstructured":"Karst AM, Drapkin R (2010) Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010:1\u201313. https:\/\/doi.org\/10.1155\/2010\/932371","journal-title":"J Oncol"},{"key":"10136_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI, Papp E, Hallberg D et al (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8:1\u201310. https:\/\/doi.org\/10.1038\/s41467-017-00962-1","journal-title":"Nat Commun"},{"key":"10136_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","volume":"29","author":"PT Kroeger","year":"2017","unstructured":"Kroeger PT, Drapkin R (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26\u201334. https:\/\/doi.org\/10.1097\/GCO.0000000000000340","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10136_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2015.00245","volume":"5","author":"A Cho","year":"2015","unstructured":"Cho A, Howell VM, Colvin EK (2015) The extracellular matrix in epithelial ovarian cancer \u2013 a piece of a puzzle. Front Oncol 5:1\u201316. https:\/\/doi.org\/10.3389\/fonc.2015.00245","journal-title":"Front Oncol"},{"key":"10136_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1074\/mcp.M111.014647","volume":"11","author":"A Naba","year":"2012","unstructured":"Naba A, Clauser KR, Hoersch S et al (2012) The matrisome: In silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 11:1\u201318. https:\/\/doi.org\/10.1074\/mcp.M111.014647","journal-title":"Mol Cell Proteomics"},{"key":"10136_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a004903","volume":"4","author":"RO Hynes","year":"2012","unstructured":"Hynes RO, Naba A (2012) Overview of the matrisome-An inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol 4:1\u201316. https:\/\/doi.org\/10.1101\/cshperspect.a004903","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10136_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15:786\u2013801. https:\/\/doi.org\/10.1038\/nrm3904","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10136_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/915140","volume":"2012","author":"K Sawada","year":"2012","unstructured":"Sawada K, Ohyagi-Hara C, Kimura T, Morishige KI (2012) Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol 2012:1\u20137. https:\/\/doi.org\/10.1155\/2012\/915140","journal-title":"J Oncol"},{"key":"10136_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/BF00159282","volume":"25","author":"FT Bosman","year":"1993","unstructured":"Bosman FT (1993) Integrins: cell adhesives and modulators of cell function. Histochem J 25:469\u2013477. https:\/\/doi.org\/10.1007\/BF00159282","journal-title":"Histochem J"},{"issue":"5","key":"10136_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/gb-2007-8-5-215","volume":"8","author":"Y Takada","year":"2007","unstructured":"Takada Y, Ye X, Simon S (2007) The integrins. Genome Biol 8(5):215. https:\/\/doi.org\/10.1186\/gb-2007-8-5-215","journal-title":"Genome Biol"},{"key":"10136_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ceb.2005.08.010","volume":"17","author":"MH Ginsberg","year":"2005","unstructured":"Ginsberg MH, Partridge A, Shattil SJ (2005) Integrin regulation. Curr Opin Cell Biol 17:509\u2013516. https:\/\/doi.org\/10.1016\/j.ceb.2005.08.010","journal-title":"Curr Opin Cell Biol"},{"key":"10136_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.cellbio.21.090704.151217","volume":"21","author":"MA Arnaout","year":"2005","unstructured":"Arnaout MA, Mahalingam B, Xiong JP (2005) Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol 21:381\u2013410. https:\/\/doi.org\/10.1146\/annurev.cellbio.21.090704.151217","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10136_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tcb.2005.06.005","volume":"15","author":"SJ Shattil","year":"2005","unstructured":"Shattil SJ (2005) Integrins and Src: Dynamic duo of adhesion signaling. Trends Cell Biol 15:399\u2013403. https:\/\/doi.org\/10.1016\/j.tcb.2005.06.005","journal-title":"Trends Cell Biol"},{"key":"10136_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2014.371","volume":"23","author":"Dr. Nicolas Rodondi, MD, MAS, Ms. W","year":"2010","unstructured":"Dr. Nicolas Rodondi, MD, MAS, Ms. Wendy P. J. den Elzen, MSc, Dr. Douglas C. Bauer, MD, Dr. Anne R. Cappola, MD, ScM, Dr. Salman Razvi, MD, FRCP, Dr. John P. Walsh, MBBS, FRACP, PhD, Dr. Bj\u00f8rn O. \u00c5svold, MD, PhD, Dr. Giorgio Iervasi, MD, Dr. Misa Imaizumi P, (2010) Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten Models. Bone 23:1\u20137. https:\/\/doi.org\/10.1038\/jid.2014.371","journal-title":"Bone"},{"key":"10136_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2017.01.011","volume":"176","author":"M Dean","year":"2018","unstructured":"Dean M, D.A. Davis JEB, (2018) Activin a stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non- canonical signaling. Physiol Behav 176:139\u2013148. https:\/\/doi.org\/10.1016\/j.canlet.2017.01.011","journal-title":"Physiol Behav"},{"key":"10136_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1539613","volume":"8","author":"D Newsted","year":"2019","unstructured":"Newsted D, Banerjee S, Watt K et al (2019) Blockade of TGF-\u03b2 signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models. Oncoimmunology 8:1\u201314. https:\/\/doi.org\/10.1080\/2162402X.2018.1539613","journal-title":"Oncoimmunology"},{"key":"10136_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11060838","volume":"11","author":"N Loret","year":"2019","unstructured":"Loret N, Denys H, Tummers P, Berx G (2019) The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers (Basel) 11:1\u201322. https:\/\/doi.org\/10.3390\/cancers11060838","journal-title":"Cancers (Basel)"},{"key":"10136_CR23","doi-asserted-by":"publisher","unstructured":"Perets R, Wyant GA, Muto KW, et al (2013) Transformation of the Fallopian Tube Secretory Epithelium Leads to High-grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. 24:751\u2013765. https:\/\/doi.org\/10.1016\/j.ccr.2013.10.013.","DOI":"10.1016\/j.ccr.2013.10.013"},{"key":"10136_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep06116","volume":"4","author":"Y Yang-Hartwich","year":"2014","unstructured":"Yang-Hartwich Y, Gurrea-Soteras M, Sumi N et al (2014) Ovulation and extra-ovarian origin of ovarian cancer. Sci Rep 4:1\u201312. https:\/\/doi.org\/10.1038\/srep06116","journal-title":"Sci Rep"},{"key":"10136_CR25","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, B\u00f6hm S, Ahmed AA et al (2015) Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668\u2013679. https:\/\/doi.org\/10.1038\/nrc4019","journal-title":"Nat Rev Cancer"},{"key":"10136_CR26","doi-asserted-by":"publisher","unstructured":"Doberstein K, Spivik R, Feng Y, et al (2018) Fallopian tube precursor lesions of serous ovarian carcinoma require L1CAM for dissemination and metastasis. biorxiv https:\/\/doi.org\/10.1101\/270785","DOI":"10.1101\/270785"},{"key":"10136_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O et al (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358\u2013363","journal-title":"Cancer"},{"key":"10136_CR28","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2217\/fon.10.100","volume":"6","author":"Z Lu","year":"2010","unstructured":"Lu Z, Wang J, Wientjes MG, Au JLS (2010) Intraperitoneal therapy for peritoneal cancer. Futur Oncol 6:1625\u20131641. https:\/\/doi.org\/10.2217\/fon.10.100","journal-title":"Futur Oncol"},{"key":"10136_CR29","first-page":"360","volume":"55","author":"JA Nagy","year":"1995","unstructured":"Nagy JA, Masse EM, Herzberg KT et al (1995) Pathogenesis of Ascites Tumor Growth: Vascular Permeability Factor, Vascular Hyperpermeability, and Ascites Fluid Accumulation. Cancer Res 55:360\u2013368","journal-title":"Cancer Res"},{"key":"10136_CR30","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1158\/0008-5472.CAN-08-4151","volume":"69","author":"NM Moss","year":"2009","unstructured":"Moss NM, Barbolina MV, Liu Y et al (2009) Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: A potential role in I.p. metastatic dissemination. Cancer Res 69:7121\u20137129. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4151","journal-title":"Cancer Res"},{"key":"10136_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2014.12.004","volume":"17","author":"L Weiswald","year":"2015","unstructured":"Weiswald L, Bellet D, Dangles-marie V (2015) Spherical Cancer Models in Tumor NEO 17:1\u201315. https:\/\/doi.org\/10.1016\/j.neo.2014.12.004","journal-title":"Spherical Cancer Models in Tumor NEO"},{"key":"10136_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20010229","author":"E Emmings","year":"2019","unstructured":"Emmings E, Mullany S, Chang Z et al (2019) Targeting mitochondria for treatment of chemoresistant ovarian cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20010229","journal-title":"Int J Mol Sci"},{"key":"10136_CR33","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/carcin\/bgu049","volume":"35","author":"RJM Correa","year":"2014","unstructured":"Correa RJM, Valdes YR, Peart TM et al (2014) Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability. Carcinogenesis 35:1951\u20131961. https:\/\/doi.org\/10.1093\/carcin\/bgu049","journal-title":"Carcinogenesis"},{"key":"10136_CR34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1242\/bio.2012653","volume":"1","author":"JC Pease","year":"2012","unstructured":"Pease JC, Brewer M, Tirnauer JS (2012) Spontaneous spheroid budding from monolayers: A potential contribution to ovarian cancer dissemination. Biol Open 1:622\u2013628. https:\/\/doi.org\/10.1242\/bio.2012653","journal-title":"Biol Open"},{"key":"10136_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/2321-3868.113331","volume":"1","author":"J Jiang","year":"2013","unstructured":"Jiang J, Li L, He Y, Zhao M (2013) Collective cell migration: Implications for wound healing and cancer invasion. Burn Trauma 1:21. https:\/\/doi.org\/10.4103\/2321-3868.113331","journal-title":"Burn Trauma"},{"key":"10136_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20061466","volume":"20","author":"L Moffitt","year":"2019","unstructured":"Moffitt L, Karimnia N, Stephens A, Bilandzic M (2019) Therapeutic targeting of collective invasion in Ovarian cancer. Int J Mol Sci 20:1\u201317. https:\/\/doi.org\/10.3390\/ijms20061466","journal-title":"Int J Mol Sci"},{"key":"10136_CR37","doi-asserted-by":"publisher","unstructured":"Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ (2012) Cell \u2013 cell and cell \u2013 matrix dynamics in intraperitoneal cancer metastasis. 397\u2013414. https:\/\/doi.org\/10.1007\/s10555-012-9351-2","DOI":"10.1007\/s10555-012-9351-2"},{"key":"10136_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12051250","volume":"12","author":"JL Fritz","year":"2020","unstructured":"Fritz JL, Collins O, Saxena P et al (2020) A novel role for NUAK1 in promoting ovarian cancer metastasis through regulation of fibronectin production in Spheroids. Cancers (Basel) 12:1\u201323. https:\/\/doi.org\/10.3390\/cancers12051250","journal-title":"Cancers (Basel)"},{"key":"10136_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177:1053\u20131064. https:\/\/doi.org\/10.2353\/ajpath.2010.100105","journal-title":"Am J Pathol"},{"key":"10136_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ygyno.2003.12.034","volume":"93","author":"KM Burleson","year":"2004","unstructured":"Burleson KM, Casey RC, Skubitz KM et al (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 93:170\u2013181. https:\/\/doi.org\/10.1016\/j.ygyno.2003.12.034","journal-title":"Gynecol Oncol"},{"key":"10136_CR41","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/S0002-9440(10)63058-1","volume":"159","author":"RC Casey","year":"2001","unstructured":"Casey RC, Burleson KM, Skubitz KM et al (2001) \u03921-Integrins Regulate the Formation and Adhesion of Ovarian Carcinoma Multicellular Spheroids. Am J Pathol 159:2071\u20132080. https:\/\/doi.org\/10.1016\/S0002-9440(10)63058-1","journal-title":"Am J Pathol"},{"key":"10136_CR42","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1002\/ijc.24188","volume":"124","author":"KL Sodek","year":"2009","unstructured":"Sodek KL, Ringuette MJ, Brown TJ (2009) Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 124:2060\u20132070. https:\/\/doi.org\/10.1002\/ijc.24188","journal-title":"Int J Cancer"},{"key":"10136_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00441-005-0148-2","volume":"324","author":"RZ Lin","year":"2006","unstructured":"Lin RZ, Chou LF, Chien CCM, Chang HY (2006) Dynamic analysis of hepatoma spheroid formation: Roles of E-cadherin and \u03b21-integrin. Cell Tissue Res 324:411\u2013422. https:\/\/doi.org\/10.1007\/s00441-005-0148-2","journal-title":"Cell Tissue Res"},{"key":"10136_CR44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s13277-010-0017-9","volume":"31","author":"S Kellouche","year":"2010","unstructured":"Kellouche S, Fernandes J, Leroy-Dudal J et al (2010) Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin. Tumor Biol 31:129\u2013139. https:\/\/doi.org\/10.1007\/s13277-010-0017-9","journal-title":"Tumor Biol"},{"key":"10136_CR45","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/sj.onc.1206347","volume":"22","author":"S Cruet-Hennequart","year":"2003","unstructured":"Cruet-Hennequart S, Maubant S, Luis J et al (2003) \u03b1v integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22:1688\u20131702. https:\/\/doi.org\/10.1038\/sj.onc.1206347","journal-title":"Oncogene"},{"key":"10136_CR46","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.yexcr.2013.11.011","volume":"320","author":"L Carduner","year":"2014","unstructured":"Carduner L, Picot CR, Leroy-Dudal J et al (2014) Cell cycle arrest or survival signaling through \u03b1v integrins, activation of PKC and ERK1\/2 lead to anoikis resistance of ovarian cancer spheroids. Exp Cell Res 320:329\u2013342. https:\/\/doi.org\/10.1016\/j.yexcr.2013.11.011","journal-title":"Exp Cell Res"},{"key":"10136_CR47","first-page":"514","volume":"68","author":"GE Morozevich","year":"2003","unstructured":"Morozevich GE, Kozlova NI, Chubukina AN, Berman AE (2003) Role of integrin alphavbeta3 in substrate-dependent apoptosis of human intestinal carcinoma cells. Biokhimiya 68:514\u2013522","journal-title":"Biokhimiya"},{"key":"10136_CR48","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/0008-8749(91)90296-n","volume":"135","author":"M Bellio","year":"1991","unstructured":"Bellio M, Leal LM, Scharfstein J, Dos Reis GA (1991) Interactions between CD3 and Thy1 T cell activation pathways: blockade of CD3-mediated T lymphocyte activation induced by immobilized anti-Thy1 antibodies. Cell Immunol 135:534\u2013540. https:\/\/doi.org\/10.1016\/0008-8749(91)90296-n","journal-title":"Cell Immunol"},{"key":"10136_CR49","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1242\/jcs.034827","volume":"122","author":"AM Avalos","year":"2009","unstructured":"Avalos AM, Valdivia AD, Mu\u00f1oz N et al (2009) Neuronal Thy-1 induces astrocyte adhesion by engaging syndecan-4 in a cooperative interaction with alphavbeta3 integrin that activates PKCalpha and RhoA. J Cell Sci 122:3462\u20133471. https:\/\/doi.org\/10.1242\/jcs.034827","journal-title":"J Cell Sci"},{"key":"10136_CR50","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/onc.2011.282","volume":"31","author":"J Jiang","year":"2012","unstructured":"Jiang J, Zhang Y, Chuai S et al (2012) Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene 31:671\u2013682. https:\/\/doi.org\/10.1038\/onc.2011.282","journal-title":"Oncogene"},{"key":"10136_CR51","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3892\/ijo.2016.3691","volume":"49","author":"WC Chen","year":"2016","unstructured":"Chen WC, Hsu HP, Li CY et al (2016) Cancer stem cell marker CD90 inhibits ovarian cancer formation via \u03b23 integrin. Int J Oncol 49:1881\u20131889. https:\/\/doi.org\/10.3892\/ijo.2016.3691","journal-title":"Int J Oncol"},{"key":"10136_CR52","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1158\/0008-5472.CAN-12-2991","volume":"73","author":"KH Tang","year":"2013","unstructured":"Tang KH, Dai YD, Tong M et al (2013) A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res 73:2322\u20132332. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2991","journal-title":"Cancer Res"},{"key":"10136_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2008.01.013","volume":"13","author":"ZF Yang","year":"2008","unstructured":"Yang ZF, Ho DW, Ng MN et al (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13:153\u2013166. https:\/\/doi.org\/10.1016\/j.ccr.2008.01.013","journal-title":"Cancer Cell"},{"key":"10136_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034295","author":"R Herrera-Molina","year":"2012","unstructured":"Herrera-Molina R, Frischknecht R, Maldonado H et al (2012) Astrocytic \u03b1 v\u03b2 3 integrin inhibits neurite outgrowth and promotes retraction of neuronal processes by clustering thy-1. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0034295","journal-title":"PLoS ONE"},{"key":"10136_CR55","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1172\/JCI87252","volume":"126","author":"M. Y, X. L, S. T,","year":"2016","unstructured":"M. Y, X. L, S. T, et al (2016) Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest 126:4157\u20134173. https:\/\/doi.org\/10.1172\/JCI87252","journal-title":"J Clin Invest"},{"key":"10136_CR56","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","volume":"67","author":"TM Robinson-Smith","year":"2007","unstructured":"Robinson-Smith TM, Isaacsohn I, Mercer CA et al (2007) Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 67:5708\u20135716. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4375","journal-title":"Cancer Res"},{"key":"10136_CR57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ijc.11086","volume":"106","author":"IS Patel","year":"2003","unstructured":"Patel IS, Madan P, Getsios S et al (2003) Cadherin switching in ovarian cancer progression. Int J Cancer 106:172\u2013177. https:\/\/doi.org\/10.1002\/ijc.11086","journal-title":"Int J Cancer"},{"key":"10136_CR58","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","volume":"68","author":"K Sawada","year":"2008","unstructured":"Sawada K, Mitra AK, Radjabi AR et al (2008) Loss of E-cadherin promotes ovarian cancer metastasis via \u03b15-integrin, which is a therapeutic target. Cancer Res 68:2329\u20132339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5167","journal-title":"Cancer Res"},{"key":"10136_CR59","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-06-2808","volume":"67","author":"J Symowicz","year":"2007","unstructured":"Symowicz J, Adley BP, Gleason KJ et al (2007) Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67:2030\u20132039. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2808","journal-title":"Cancer Res"},{"key":"10136_CR60","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/0008-5472.CAN-06-1147","volume":"67","author":"K Sawada","year":"2007","unstructured":"Sawada K, Radjabi AR, Shinomiya N et al (2007) c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67:1670\u20131679. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1147","journal-title":"Cancer Res"},{"key":"10136_CR61","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.fertnstert.2009.06.039","volume":"94","author":"C Banz","year":"2010","unstructured":"Banz C, Ungethuem U, Kuban RJ et al (2010) The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril 94:1212\u20131217. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.06.039","journal-title":"Fertil Steril"},{"key":"10136_CR62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1530\/ERC-15-0383","volume":"23","author":"S Rafehi","year":"2016","unstructured":"Rafehi S, Valdes YR, Bertrand M et al (2016) TGF\u03b2 signaling regulates Epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids. Endocr Relat Cancer 23:147\u2013159. https:\/\/doi.org\/10.1530\/ERC-15-0383","journal-title":"Endocr Relat Cancer"},{"key":"10136_CR63","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.4161\/cc.9.8.11517","volume":"9","author":"A Bianchi","year":"2010","unstructured":"Bianchi A, Gervasi ME, Bakin AV (2010) Role of \u03b25-integrin in epithelial-mesenchymal transition in response to TGF\u03b2. Cell Cycle 9:1647\u20131659. https:\/\/doi.org\/10.4161\/cc.9.8.11517","journal-title":"Cell Cycle"},{"key":"10136_CR64","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.12659\/MSM.911518","volume":"24","author":"J He","year":"2018","unstructured":"He J, Liu Y, Zhang L, Zhang H (2018) Integrin subunit beta 8 (ITGB8) upregulation is an independent predictor of unfavorable survival of high-grade serous ovarian carcinoma patients. Med Sci Monit 24:8933\u20138940","journal-title":"Med Sci Monit"},{"key":"10136_CR65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre A, Weinberg RA (2019) New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20:69\u201384. https:\/\/doi.org\/10.1038\/s41580-018-0080-4","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10136_CR66","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10585-004-5768-5","volume":"21","author":"KM Burleson","year":"2005","unstructured":"Burleson KM, Hansen LK, Skubitz APN (2005) Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin Exp Metastasis 21:685\u2013697. https:\/\/doi.org\/10.1007\/s10585-004-5768-5","journal-title":"Clin Exp Metastasis"},{"key":"10136_CR67","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1006\/gyno.1999.5388","volume":"73","author":"T Strobel","year":"1999","unstructured":"Strobel T, Cannistra SA (1999) \u03921-Integrins Partly Mediate Binding of Ovarian Cancer Cells To Peritoneal Mesothelium in Vitro. Gynecol Oncol 73:362\u2013367. https:\/\/doi.org\/10.1006\/gyno.1999.5388","journal-title":"Gynecol Oncol"},{"key":"10136_CR68","first-page":"11","volume":"15","author":"T Kishikawa","year":"1995","unstructured":"Kishikawa T, Sakamoto M, Ino Y et al (1995) Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models. Invasion Metastasis 15:11\u201321","journal-title":"Invasion Metastasis"},{"key":"10136_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI114957","volume":"87","author":"E Ruoslahti","year":"1991","unstructured":"Ruoslahti E (1991) Integrins. J Clin Invest 87:1\u20135. https:\/\/doi.org\/10.1172\/JCI114957","journal-title":"J Clin Invest"},{"key":"10136_CR70","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.2353\/ajpath.2009.090028","volume":"175","author":"S Kaur","year":"2009","unstructured":"Kaur S, Kenny HA, Jagadeeswaran S et al (2009) \u03923-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 175:2184\u20132196. https:\/\/doi.org\/10.2353\/ajpath.2009.090028","journal-title":"Am J Pathol"},{"key":"10136_CR71","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.0.CO;2-4","volume":"67","author":"TL Moser","year":"1996","unstructured":"Moser TL, Pizzo SV, Bafetti LM et al (1996) Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the \u03b12\u03b21 integrin. Int J Cancer 67:695\u2013701. https:\/\/doi.org\/10.1002\/(SICI)1097-0215(19960904)67:5%3c695::AID-IJC18%3e3.0.CO;2-4","journal-title":"Int J Cancer"},{"key":"10136_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-3163-6-11","volume":"6","author":"K Shield","year":"2007","unstructured":"Shield K, Riley C, Quinn MA et al (2007) \u03912\u03921 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 6:1\u201315. https:\/\/doi.org\/10.1186\/1477-3163-6-11","journal-title":"J Carcinog"},{"key":"10136_CR73","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0090-8258(03)00321-4","volume":"90","author":"B Davidson","year":"2003","unstructured":"Davidson B, Goldberg I, Reich R et al (2003) \u0391v- and \u03921-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 90:248\u2013257. https:\/\/doi.org\/10.1016\/S0090-8258(03)00321-4","journal-title":"Gynecol Oncol"},{"key":"10136_CR74","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1158\/0008-5472.CAN-08-2678","volume":"69","author":"JK Slack-Davis","year":"2009","unstructured":"Slack-Davis JK, Atkins KA, Harrer C et al (2009) Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 69:1469\u20131476. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2678","journal-title":"Cancer Res"},{"key":"10136_CR75","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1158\/2159-8274.CD-11-0010","volume":"23","author":"MP Iwanicki","year":"2011","unstructured":"Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T (2011) Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov 23:144\u2013157. https:\/\/doi.org\/10.1158\/2159-8274.CD-11-0010","journal-title":"Cancer Discov"},{"key":"10136_CR76","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0090-8258(02)00152-X","volume":"89","author":"R Kokenyesi","year":"2003","unstructured":"Kokenyesi R, Murray KP, Benshushan A et al (2003) Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: Role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression. Gynecol Oncol 89:60\u201372. https:\/\/doi.org\/10.1016\/S0090-8258(02)00152-X","journal-title":"Gynecol Oncol"},{"key":"10136_CR77","first-page":"985","volume":"4","author":"R Giavazzi","year":"1998","unstructured":"Giavazzi R, Garofalo A, Ferri C et al (1998) Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin cancer Res an Off J Am Assoc Cancer Res 4:985\u2013992","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"key":"10136_CR78","doi-asserted-by":"crossref","unstructured":"Ahmed N, Pansino F, Clyde R, et al (2002) Overexpression of \u03b1v\u03b26 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. 23:237\u2013244","DOI":"10.1093\/carcin\/23.2.237"},{"key":"10136_CR79","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1172\/JCI33775","volume":"118","author":"HA Kenny","year":"2008","unstructured":"Kenny HA, Kaur S, Coussens LM, Lengyel E (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 118:1367\u20131379. https:\/\/doi.org\/10.1172\/JCI33775","journal-title":"J Clin Invest"},{"key":"10136_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9\u201322. https:\/\/doi.org\/10.1038\/nrc2748","journal-title":"Nat Rev Cancer"},{"key":"10136_CR81","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/9511","volume":"5","author":"T Sethi","year":"1999","unstructured":"Sethi T, Rintoul RC, Moore SM et al (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5:662\u2013668. https:\/\/doi.org\/10.1038\/9511","journal-title":"Nat Med"},{"key":"10136_CR82","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","volume":"121","author":"KM Bell-Mcguinn","year":"2011","unstructured":"Bell-Mcguinn KM, Matthews CM, Ho SN et al (2011) A phase II, single-arm study of the anti-\u03b15\u03b21 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121:273\u2013279. https:\/\/doi.org\/10.1016\/j.ygyno.2010.12.362","journal-title":"Gynecol Oncol"},{"key":"10136_CR83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/17425240903468696","volume":"7","author":"Z Wang","year":"2010","unstructured":"Wang Z, Chui WK, Ho PC (2010) Integrin targeted drug and gene delivery. Expert Opin Drug Deliv 7:159\u2013171. https:\/\/doi.org\/10.1517\/17425240903468696","journal-title":"Expert Opin Drug Deliv"},{"key":"10136_CR84","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1158\/1535-7163.MCT-06-0100","volume":"5","author":"P Khalili","year":"2006","unstructured":"Khalili P, Arakelian A, Chen G et al (2006) A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 5:2271\u20132280. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0100","journal-title":"Mol Cancer Ther"},{"key":"10136_CR85","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1158\/1078-0432.CCR-07-4530","volume":"14","author":"F Do\u00f1ate","year":"2008","unstructured":"Do\u00f1ate F, Parry GC, Shaked Y et al (2008) Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH 2): Observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 14:2137\u20132144. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4530","journal-title":"Clin Cancer Res"},{"key":"10136_CR86","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1593\/neo.08740","volume":"10","author":"CN Landen","year":"2008","unstructured":"Landen CN, Kim TJ, Lin YG et al (2008) Tumor-selective response to antibody-mediated targeting of \u03b1v\u03b23 integrin in ovarian cancer. Neoplasia 10:1259\u20131267. https:\/\/doi.org\/10.1593\/neo.08740","journal-title":"Neoplasia"},{"key":"10136_CR87","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/IGC.0b013e3182187324","volume":"21","author":"M Bellone","year":"2011","unstructured":"Bellone M (2011) Expression of \u03b1V-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti\u2013\u03b1V- integrin antibody. Int J Gynecol Cancer 21:1084\u20131090. https:\/\/doi.org\/10.1097\/IGC.0b013e3182187324","journal-title":"Int J Gynecol Cancer"},{"key":"10136_CR88","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1200\/JCO.2006.06.6514","volume":"25","author":"LB Nabors","year":"2007","unstructured":"Nabors LB, Mikkelsen T, Rosenfeld SS et al (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651\u20131657. https:\/\/doi.org\/10.1200\/JCO.2006.06.6514","journal-title":"J Clin Oncol"},{"key":"10136_CR89","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, L\u00f5hmussaar K et al (2019) An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med 25:838\u2013849. https:\/\/doi.org\/10.1038\/s41591-019-0422-6","journal-title":"Nat Med"},{"issue":"7","key":"10136_CR90","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/cancers9070083","volume":"9","author":"M Kobayashi","year":"2017","unstructured":"Kobayashi M, Sawada K, Kimura T (2017) Potential of integrin inhibitors for treating ovarian cancer: A literature review. Cancers (Basel) 9(7):83. https:\/\/doi.org\/10.3390\/cancers9070083","journal-title":"Cancers (Basel)"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-021-10136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-021-10136-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-021-10136-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:33:49Z","timestamp":1648737229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-021-10136-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10136"],"URL":"https:\/\/doi.org\/10.1007\/s10585-021-10136-5","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"8 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}